KT 100 KISTOCK Temperature datalogger Measure up to 2 parameters LCD display With or without external input Fast data download (1,000 values/second) Upt to 12,000 measurement points 2 configurable setpoint alarms Small dimensions Magnetic mounting With or without IP 67 or IP 40 housing and Elastomer protection pads
Some reviews of clomid noted that the drug can also cause weight gain, hair loss and vision impairment Problems with impregnation Product description posted on this page is a supplement and a simplified version of the official version of the annotations to the drug.Cialis ne doit pas être prise à tous. Il est important que cialis en ligne est prescrit par un médecin, bien se familiariser avec les antécédents médicaux du patient. Ich habe Probleme mit schnellen Montage. Lesen Sie Testberichte Nahm wie cialis rezeptfrei 30 Minuten vor dem Sex, ohne Erfolg. Beginn der Arbeiten nach 4 Stunden, links ein Freund ein trauriges Ja, und Schwanz in sich selbst nicht ausstehen, wenn es keinen Wunsch ist.
Metformin as a novel component of metronomic chemotherapeutic use: a hypothesis
Contents lists available at Journal of Experimental and Clinical Medicine Metformin as a Novel Component of Metronomic Chemotherapeutic Use:A Hypothesis Jorge Eduardo Duque , Juliana Velez Ismael Samudio Enoch Lai 1 Grupo de Terapia Celular y Molecular, Pontiﬁcia Universidad Javeriana, Bogotá DC, Colombia 2 Centro Oncológico de Antioquia, Medellín, Colombia3 Shuang Ho Medical Hospital, Taipei Medical University, Taipei, Taiwan The hypoglycemic agent metformin has been found to possess chemopreventive and direct antitumor properties. Several clinical studies worldwide are using it as a monotherapy or as an add-on therapy with Received: Jan 25, 2011 chemotherapeutic drugs to determine prospectively its efﬁcacy and safety in treating human cancer. In Revised: Nov 5, 2011 terms of its mechanism of action, metformin moderately inhibits electron transport in mitochondria to Accepted: Nov 30, 2011 cause increased AMP:ATP ratios, which antagonize gluconeogenesis in hepatocytes, and to promotecatabolism in most tissues through activating AMP-activated kinase (AMPK). Inhibition of mammalian target of rapamycin signaling through activation of AMPK has been suggested to mediate the antitumor effects of metformin. However, AMPK-independent growth-inhibitory properties of metformin on tumor cells have also been described, suggesting that antagonizing electron transport per se may be cytostatic or cytotoxic to cancer cells. In addition, metformin was hypothesized to display antiviral and antimalarial effects in 1950s, and recently it has been found to promote the generation of CD8 T memory lympho- metronomic chemotherapy cytes, suggesting that its immune-activating effects may also contribute to its observed antitumor andchemopreventive properties. Chronic administration of metformin has an acceptable toxicity proﬁle andis well tolerated by millions of patients with type 2 diabetes worldwide, suggesting that this agent couldpotentially be a therapeutic component with low intensity if given in continuous dosing/frequent usageschedules. These metronomic strategies show that metformin can inhibit tumor angiogenesis and acti-vate antitumor immunity, indicating a potential therapeutic interaction with immune potentiation,antitumor effects, and an acceptable toxicity proﬁle. Here, we review current knowledge on metformin'ssignaling, metabolic, and immune effects, as well as data from clinical drug trials, to discuss how theinterplay may orchestrate the antitumor effects of this agent, particularly in combination with reduced-intensity or metronomic chemotherapeutic use.
Copyright Ó 2012, Taipei Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
2. Major mechanisms related to antitumor effects ofmetformin Metformin, a biguanide, was approved by the United States Foodand Drug Administration in 1995 as an oral hypoglycemic agent.
The mechanisms underlying the action of metformin in exerting Given alone or in combination with a sulfonylurea, metformin antitumor effects can be summarized as follows.
improves glycemic control and lipid concentrations in patients whorespond poorly to dietary control or to a sulfonylurea alone.
2.1. Metabolic and signaling effects In this review, we discuss evidence for metformin's potential use as an antitumor drug. We will review the major mechanisms Anisimov et al, in their pioneer work to understand the antitumor related to its antitumor effects, clinical evidence of its antitumor mechanism of metformin, found that chronic administration of and chemopreventive effects, metronomic chemotherapydwhen metformin to female transgenic HER2/neu mice signiﬁcantly reduced less is moredand the interaction of metronomic chemotherapy the number and size of mammary adenocarcinomas, partly through and metformin.
downregulation of the insulin/insulin-like growth factor axis (IGF).This mechanism has already been observed in patients with type 2diabetand women affected by polycystic ovary syndrome.
* Corresponding author. Ismael Samudio, 301 Ediﬁcio Jesús Emilio Ramírez, More recent experimental evidence indicates that this Pontiﬁcia Universidad Javeriana, Cra 7 Number 43e82, Bogotá, Colombia.
E-mail: I. Samudio > biguanide can activate AMP-dependent kinase (AMPK), either by 1878-3317/$ e see front matter Copyright Ó 2012, Taipei Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
Metformin as a novel component of metronomic chemotherapy schemes 2.3. Immune and hypothalamic effects promoting an increase in AMP:ATP ratiosActivated AMPK canin turn phosphorylate and activate TSC2, a negative regulator of It is important to consider immune-modulating effects of metfor- mammalian target of rapamycin Inhibiting mTOR min as a mechanism underlying antitumor activity. This concept kinase activity can reduce signaling transduction through the was originally proposed in the 1950s by the Philippine physician kinase Akt, and decrease the efﬁciency of protein synthesis via Garcia,who ﬁrst recognized the important component of the decreased phosphorylation of the mTOR targets 4EBP-1 and S6K, antitumor effects of metformin. A recent thought-provoking report which are essential components of the cap-dependent trans- has shown that metformin can increase the number memory CD8 T lation machineryThe inhibition of cap-dependent translation cells in wildtype mice, and in consequence signiﬁcantly improve in response to metformincan result in decreased expression of the efﬁcacy of an experimental anticancer vThis report the oncogene Her2and the cell cycle protein cyclin D1, suggested the mechanism that increased fatty acid oxidation in illustrating a potential avenue via which metformin can modu- response to metformin can mediate the generation of CD8 T cells.
late signaling and cell cycle effects.
However, this notion does not agree with the observation that Because AMPK is the energy sensor of the cell, metformin metformin inhibits electron transport in hepatocytes and hepato- also increases oxidative metabolism and reduces anabolism, cyte mitochondria, and it is thus intriguing to hypothesize that resulting in decreased lipid synthesis, protein synthesis, and so metformin modulates tissue-speciﬁc responses in mitochondrial on,in part through direct phosphorylation effects on key metabolism by inhibiting electron transport in hepatocytes instead metabolic targets such as acetyl CoA carboxylase (a committed of promoting fatty acid oxidation in lymphocytes. Irrespective of step in fatty acid synthesis) and phosphofructokinase-2 (the this, the mechanism for the generation of memory CD8 T cells could master regulator of glycolysis).How metformin activates LKB1 be a critical component of the antitumor action of metformin.
remains unclear, but it has been shown that metformin can Lastly, Ropelle et al have shown that hypothalamic AMPK acti- increase the AMP:ATP ratio, the canonical signal to activate vation in response to metformin reverses cancer anorexia in tumor- AMPK, as a result of moderate inhibition of the electron trans- bearing rats through inhibiting the production of proinﬂammatory port chain at the entry point of NADH, the mitochondrial molecules and controlling neuropeptide expression in the hypo- thalamus,suggesting another potential beneﬁt of the use of This latter evidence is also intriguing in light of Anisimov et al's metformin as an adjuvant in cancer treatment, which warrants original ﬁndings that metformin can also prolong the life span of further clinical exploration.
Her2 mice, because it highlights the possibility that the reduction inmitochondrial bioenergetics induced by metformin may be the 2.4. Metformin might have multiple mechanisms in exerting its cellular mimic of caloric restriction, a well-documented longevity and chemopreventive strategy.
Taken together, the observations described above indicate that the 2.2. Direct mitochondrial effects beneﬁcial effects of metformin as an adjuvant in cancer treatmentmay be orchestrated via many (AMPK-dependent and -indepen- Both the AMPK-independent antitumor effects of metformin dent) mechanisms that might antagonize tumor initiation and/or action, such as the Rag GTPase-dependent inhibition of mTOR, progression, decrease cancer anorexia, and improve antitumor and metformin-induced growth inhibition of AMPK-silenced ovarian cancer cells are important.Nearly 10 years ago, Owenet al described how metformin can inhibit the mitochondrial 3. Clinical evidence for the antitumor and chemopreventive oxidation of complex I-dependent substrates in hepatocytes, an effects of metformin effect that can also be observed in isolated mitochondria.Asdiscussed above, this inhibition of complex I may contribute to the Recently, the Zwolle Outpatient Diabetes Project Integrating activation of AMPK due to the decrease in capacity for oxidative Available Care (ZODIAC) study in The Netherlands reported that phosphorylation and the subsequent increase in AMP:ATP ratio.
metformin exerts chemoprotective activity against all types of This phenomenon may also account for the occasionally observed cancer in patients with type 2 diabetes.Retrospective studies by lactic acidosis in response to high doses of because a group from the University of Washington at Seattle, USA,and pyruvate is converted to lactate rather than to acetyl CoA in the another group from M. D. Anderson Cancer Center in Houston, conﬁrmed that patients with type 2 diabetes treated with The inhibition of hepatic gluconeogenesis in response to metformin had a reduced risk of prostate and pancreatic cancer, metformin is an AMPK-independent consequence of decreased intracellular ATP levels.This notion suggests that the pleio- Based on the available clinical and experimental data, Goodwin, tropic effects of metformin could be the result of a targeted in an editorial in the 2009 Journal of Clinical Oncology, proposed the effect on electron transport in the mitochondria.In light of use of metformin in the adjuvant treatment of breast cancer recent observations, this intriguing effect shows that inhibiting mainly citing the drug's ability to reduce h electron transport in cancer cells is a lethal insult,not which she had reported to be a negative prognostic factor for because of an ensuing energetic catastrophe - cancer cells derive recurrence.Of note, reduction in insulin level and the associated most of their ATP from glycolysis - but because the accumula- decrease in IGF-1 signaling transduction were also suggested to be tion of NADH in the mitochondrial matrix can inhibit the Krebs a mechanism of action in the studies of Anisimov et al.
cycle and the associated amphibolic reactions that support the The ﬁrst evidence of the efﬁcacy and safety of metformin as an generation of biomass.
adjuvant in the treatment of breast cancer was reported by the Electron transport, uncoupled from oxidative phosphorylation, breast medical oncology group at M. D. Anderson Cancer Center in antagonizes the onset of apoptosis in tumor This a retrospective study of 68 diabetic patients taking metformin, 87 supports the hypothesis that the antitumor and chemosensitizing diabetic patients not taking metformin, and 2,374 nondiabetic effects of metformin could also be mediated through inhibiting patients.Their results showed that diabetic patients with breast electron transport in complex I.
cancer who received metformin and neoadjuvant therapy had
J.E. Duque et al.
a higher pathological response rate than diabetic patients not consecutive days, followed by 3e4-week periods of rest to allow receiving this agent. Importantly, the use of metformin was not recovery of normal progenitor However, the fact that most associated with adverse effects in cancer patients receiving cancer patients still suffer relapses suggests that high-dose chemotherapy is largely ineffective in killing 100% of tumor cells, Subsequently, Stanosz reported that treatment with metformin and perhaps that the genomic instability caused by high-dose in combination with hormonal agents in young women with well- deﬁned stage 1 endometrial carcinoma led to complete remission damage DNA or the machinery necessary for its maintenance/ of the disease after a 6-month treatment and 2-year follow replicationdis the ﬁre that the cellular heterogeneity of tumors These ﬁndings suggest that the potential therapeutic beneﬁts of fuels in choosing drug-resistant subclones that will no longer metformin are not limited to breast cancers. Most recently, a group respond to the MTD approach. Moreover, the inhibitory effects of at Yokohama City University reported that a 1-month treatment high-dose chemotherapy on the function of the immune system with metformin reduced the formation of aberrant crypt foci in may provide a window of time for these drug-resistant cells to nine patients without diabetes, suggesting a potential use of met- escape detection and/or to formin in preventing colon tumorigen Interestingly, recent evidence shows that targeted anti- Taken together, the above-mentioned results and observations angiogenic agents provide a moderate therapeutic beneﬁt in many suggest that chronic use of metformin antagonizes the initiation cancer supporting a concept put forward nearly 40 years and progression of cancer, as well as improving the outcome of ago by Folkman, who proposed targeting the tumor vasculature traditional chemotherapeutic strategies.
instead of the tumor cell per se in order to inhibit the growth ofprimary tumors and the spread of malignant cells to distant 4. Metronomic chemotherapy: When less is more sites.In this context, a preponderance of evidence suggests thatlow-dose, continuous infusion or frequent administration of Traditional anticancer drugs are used at or near the maximum agentsdbut not high-dose MTD tolerated dose (MTD), with the goal of killing as many cancer cells approachesdcan inhibit the proliferation and differentiation of as possible, but with unintended consequences that impair quality tumor vasculaturIn terms of its mechanism of action, the of life and cause serious, dose-accumulative toxic To slowly proliferating phenotype of tumor vasculature, and the balance the efﬁcacy and safety of this "MTD approach" with increased sensitivity of endothelial cells to cellular damage in particular emphasis on reducing myelosuppressive effects, high response to cytotoxic agents likely makes the tumor endothelium doses of chemotherapy are normally given once or on a few more sensitive to continuous, low-dose exposure to chemotherapy Figure 1 Diagrammatic representation of the mechanism of action of metformin, which may interact with metronomic chemotherapy at various levels. (1) Metformin can promotethe generation of CD8 memory T lymphocytes, which would complement the reduction in T regulatory lymphocytes and enhance the maturation of dendritic cells induced bymetronomic chemotherapy. (2) Inhibition of mTOR signaling coupled to the decrease in mitochondrial bioenergetics induced by metformin would generate more slowly prolif-erating, chemosensitive tumor cells that would be more appropriately targeted by reduced-intensity chemotherapeutic drugs. (3) Metformin inhibits the EMT transcriptionalprogram, which effectively reduces the formation of tumor stroma and could potentiate the antiangiogenic effects of metronomic chemotherapy. (4) Metformin antagonizes theexpression of P-glycoprotein (P-gp), which could maximize the cytotoxic effects of low doses of chemotherapy in cancer cells.(5) Metformin activates hypothalamic AMPK andmay antagonize cancer cachexia, a beneﬁt most likely maximized in patients receiving metronomic regimens that are not anorexigenic or gastrotoAMP ¼ adenosinemonophosphate; AMPK ¼ AMP-activated kinase; ATP ¼ adenosine triphosphate; EMT ¼ epithelial-mesenchymal transition; mTOR, mammalian target of rapamycin.
Metformin as a novel component of metronomic chemotherapy schemes than to episodic near-MTD therapy. In 2000, Hanahan et al referred that they do to the immune system, yet they continue to be to this low-dose, continuous dosing strategy as "metronomic," and a mainstay of cancer therapy. Moreover, the devastating effects of suggested that its reduced systemic toxicity and its ability to target traditional treatment approaches, and the cost of dealing with the endothelial cells and slowly proliferating tumor cells could offer associated complications, reveal the urgency of developing potential clinical beneﬁts.
chemotherapeutic strategies that lessen suffering, optimize costs, More recent clinical studies have shown that metronomic and allow the immune system to detect and destroy malignant chemotherapy is a potential clinical alternative to either primary systemic therapy or maintenance therapy, and preclinical studies Metformin is an effective and safe hypoglycemic drug with have suggested that, in addition to its well-established anti- a potential new indication for managing and preventing cancer. The angiogenic effects, metronomic chemotherapy can activate anti- evidence presented here suggests that metformin displays single- tumor immunity. The mechanisms underlying the activation of agent therapeutic efﬁcacy, at least in the setting of chemo- antitumor immunity by metronomic chemotherapy have only prevention, and that it combines favorably with chemotherapy to recently been uncovered as most animal models are immunodeﬁ- provide cancer patients with a therapeutic beneﬁt. The above cient, but a number of published studies suggest that the effects are therapeutic considerations, and in addition the low economic cost orchestrated by a reduction in T regulatory lymphocytes, and the of metformin and metronomic chemotherapeutic regimens, maturation and activation of antigen-presenting dendritic cells.
warrant the initiation and support of additional clinical studies toevaluate the efﬁcacy of metformin in patient populations that are 5. How can metronomic chemotherapy interact with not eligible for standard anticancer regimens. This may represent a novel paradigm for the treatment of human malignancies thatreduces the costs of initial treatment and management of As shown by Anisimov et phenformin potentiates the effects of treatment-related complications, which place such a heavy burden cyclophosphamide on various transplantable tumors, and recent on health systems around the globe.
evidence suggests that antagonizing mitochondrial bioenergeticspotentiates the therapeutic effects of cytarabine in mice trans- planted with human Those ﬁndings support the notionthat metformin could potentiate the effects of traditional chemo- This work was supported in part by funds from the Research therapeutic agents. Indeed, Jiralerspong and colleagues showed Rectorate and the Department of Nutrition and Biochemistry of the retrospectively that metformin potentiates the pathological Pontiﬁcia Universidad Javeriana. The authors thank Ludis Morales response to neoadjuvant chemotherapy in diabetic breast cancer and Ingrid Schuler for scientiﬁc and administrative support, and patients without any evidence of increased toxicity.
Angelica Pinzón for technical support.
Could metformin potentiate the effects of metronomic chemo- therapy? The evidence discussed so far suggests that metformincan interact at various levels with metronomic chemotherapy.
is a schematic illustration of the mechanisms of action that 1. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, ought to be taken into consideration when incorporating metfor- Zabezhinski MA, Kovalenko IG, et al. Effect of metformin on life span and on the min into a metronomic therapeutic strategy.
development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Exp Gerontol 2005;40:685e93.
2. Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn2010;10:509e19.
At the time of writing, a search of the Clinical Trials 3. Motta AB. Mechanisms involved in metformin action in the treatment of website yielded 23 open, actively recruiting polycystic ovary syndrome. Curr Pharm Des 2009;15:3074e7.
4. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, studies in North America evaluating the efﬁcacy and/or safety of et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic treating cancer patients with metformin. Eleven of these studies effects of metformin. Science 2005;310:1642e6.
are aimed at breast cancer patients, three studies are enrolling 5. Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, et al. Metformin inhibits hepatic gluconeogenesis in mice inde- colorectal cancer patients, and the remaining studies are enrolling pendently of the LKB1/AMPK pathway via a decrease in hepatic energy state.
patients with prostatic (n ¼ 2), pancreatic (n ¼ 2), esophageal J Clin Invest 2010;120:2355e69.
(n ¼ 1), endometrial (n ¼ 1), head and neck (n ¼ 1), brain (n ¼ 1), 6. Sun Y, Fang Y, Yoon MS, Zhang C, Roccio M, Zwartkruis FJ, Armstrong M, et al.
Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad advanced-stage (n ¼ 1), and other various types (n ¼ 1) of cancer.
Sci U S A 2008;105:8286e91.
One prostate cancer study and three breast studies are using 7. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have metformin as a single agent before surgery to evaluate the molec- distinct effects on the AKT pathway and proliferation in breast cancer cells.
Breast Cancer Res Treat 2010;123:271 ular correlates of response (immunohistochemistry for cell cycle 8. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma proteins, proliferation markers, etc.), while the other prostate cell growth through activation of Akt/mammalian target of rapamycin/S6 cancer study is using metformin as a single agent in castration- kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Cancer Res 2006;66:315 resistant prostate cancer and evaluates prostate-speciﬁc antigen 9. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits levels as a primary outcome. The remaining studies are evaluating mammalian target of rapamycin-dependent translation initiation in breast the safety of combining metformin with tyrosine kinase (erlotinib cancer cells. Cancer Res 2007;67:10804e12.
or lapatinib), mTOR inhibitors (sirolimus, temsirolimus), and/or 10. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibi- traditional high-dose chemotherapy (cisplatin, epirubicin, capeci- tion of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle tabine, gemcitabine). To our knowledge, there are no registered clinical trials using metformin in combination with low-intensity 11. Ben SI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and metronomic regimens for the treatment of human malignancies.
in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576e86.
Why combine metformin, which inhibits mTOR signaling on its 12. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of own, with an mTOR inhibitor that causes immunosuppression? metabolism and cell growth. Future Oncol 2010;6:457e70.
13. Cao C, Lu S, Kivlin R, Wallin B, Card E, Bagdasarian A, Tamakloe T, et al. SIRT1 Why combine metformin with high-dose chemotherapy? Tradi- confers protection against UVB- and H2O2-induced cell death via modulation tional anticancer treatments do not take into account the damage of p53 and JNK in cultured skin keratinocytes. J Cell Mol Med 2009;13:3632e43.
J.E. Duque et al.
14. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti- 30. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin- diabetic effects through inhibition of complex 1 of the mitochondrial respira- lowering effects of metformin in women with early breast cancer. Clin Breast tory chain. Biochem J 2000;348:607e14.
15. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, et al.
31. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent Hartwick W, et al. Fasting insulin and outcome in early-stage breast cancer: manner. Cell Metab 2010;11:390e401.
results of a prospective cohort study. J Clin Oncol 2002;20:42e51.
16. Rattan R, Giri S, Hartmann L, Shridhar V. Metformin attenuates ovarian cancer cell 32. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, growth in an AMP-kinase dispensable manner. Cell Mol Med 2011;15:166e78.
Hsu L, et al. Metformin and pathologic complete responses to neoadjuvant 17. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal chemotherapy in diabetic patients with breast cancer. J Clin Oncol lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;4:CD002967.
33. Stanosz S. An attempt at conservative treatment in selected cases of type I 18. Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M, Dunner Jr K, endometrial carcinoma (stage I a/G1) in young women. Eur J Gynaecol Oncol et al. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12- dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in 34. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, chronic myeloid leukemia cells. Mol Cancer Ther 2008;7:1130e9.
et al. Metformin suppresses colorectal aberrant crypt foci in a short-term 19. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, clinical trial. Cancer Prev Res (Phila) 2010;3:1077e83.
Dunner Jr K, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes 35. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet human leukemia cells to apoptosis induction. J Clin Invest 2010;120:142e56.
20. Samudio I, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann W, Ying Y, 36. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale et al. A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 for new directions. Nat Rev Clin Oncol 2010;7:455e65.
diene-28-oate (CDDO-Me): direct permeabilization of the inner mitochon- 37. Moschetta M, Cesca M, Pretto F, Giavazzi R. Angiogenesis inhibitors: implica- drial membrane to inhibit electron transport and induce apoptosis. Mol Phar- 21. Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg 38. Folkman J. Tumor angiogenesis: role in regulation of tumor growth. Symp Soc effect: molecular basis for the reprogramming of cancer cell metabolism.
Dev Biol 1974;30:43e52.
Cancer Res 2009;69:2163e6.
39. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann 22. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The Warburg effect in Intern Med 1975;82:96e100.
leukemia-stroma cocultures is mediated by mitochondrial uncoupling associ- 40. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marmé D, et al. Anti- ated with uncoupling protein 2 activation. Cancer Res 2008;68:5198e205.
angiogenic potency of various chemotherapeutic drugs for metronomic 23. Garcia EY. Fluamine, a new synthetic analgesic and antiﬂu drug. J Philipp Med chemotherapy. Anticancer Res 2004;24:1759e63.
41. Lam T, Hetherington JW, Greenman J, Little S, Maraveyas A. Metronomic 24. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, et al.
chemotherapy dosing-schedules with estramustine and temozolomide act Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. Acta Oncol 2007;46:1169e77.
25. Ropelle ER, Pauli JR, Zecchin KG, Ueno M, de Souza CT, Morari J, Faria MC, et al.
42. Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, Fukushima M. Anti- A central role for neuronal adenosine 50-monophosphate-activated protein angiogenic effect of 5-ﬂuorouracil-based drugs against human colon cancer kinase in cancer-induced anorexia. Endocrinology 2007;148:5220e9.
xenografts. Cancer Lett 2008;267:26e36.
26. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ.
43. Stoelting S, Trefzer T, Kisro J, Steinke A, Wagner T, Peters SO. Low-dose oral Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC- metronomic chemotherapy prevents mobilization of endothelial progenitor 16. Diabetes Care 2010;33:322e6.
cells into the blood of cancer patients. In Vivo 2008;22:831e6.
27. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: 44. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing results from a population-based case-control study. Cancer Causes Control of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 28. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies 45. Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, Kwon KI, et al. Met- affect risk of pancreatic cancer. Gastroenterology 2009;137:482e8.
formin inhibits P-glycoprotein expression via the NF-kappaB pathway and 29. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for CRE transcriptional activity through AMPK activation. Br J Pharmacol action. J Clin Oncol 2009;27:3271e3.
Proyecto realizado por:Edurne Elorriaga ZugazagaWilliam Restrepo RestrepoBiotza Zulueta San Nicolás Con la colaboración de:Natxo Martínez Rueda, profesor de la Universidad de Deusto Los contenidos de esta publicación, en la presente edición, se publican bajo la licencia: Recono-cimiento-No comercial-Sin obras derivadas 3.0 España de Creative Commons. Más información: http://creativecommons.org/licenses/by-nc-nd/3.0/deed.es